|
|
Article: Novo-Nordisk 2nd to abandon effort for inhaled insulin.
- Article from:
- Biomedical Business & Technology
- Article date:
- February 1, 2008
CopyrightCOPYRIGHT 2008 AHC Media LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Novo-Nordisk 2nd to abandon effort for inhaled insulin
By DON LONG
BB&T Executive Editor
Inhaled insulin, the alternative to needle injection of insulin -- very likely to be the next big drug/device combination since the approval of drug-eluting stents.
Inhaled insulin -- likely to be the next blockbuster, given the size of the population of those with diabetes looking for faster, easier methods for controlling their meteabolism.
Inhaled insulin -- a lock for big profits.
Apparently not, for all of the above.